These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 1736531)

  • 1. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.
    Pincus S; Mason PW; Konishi E; Fonseca BA; Shope RE; Rice CM; Paoletti E
    Virology; 1992 Mar; 187(1):290-7. PubMed ID: 1736531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b.
    Putnak JR; Schlesinger JJ
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1697-702. PubMed ID: 2144016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection.
    Mason PW; Pincus S; Fournier MJ; Mason TL; Shope RE; Paoletti E
    Virology; 1991 Jan; 180(1):294-305. PubMed ID: 1845826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant baculoviruses expressing yellow fever virus E and NS1 proteins elicit protective immunity in mice.
    Desprès P; Dietrich J; Girard M; Bouloy M
    J Gen Virol; 1991 Nov; 72 ( Pt 11)():2811-6. PubMed ID: 1834798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice.
    Fonseca BA; Pincus S; Shope RE; Paoletti E; Mason PW
    Vaccine; 1994; 12(3):279-85. PubMed ID: 8165861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.
    Hahn YS; Lenches EM; Galler R; Rice CM; Dalrymple J; Strauss JH
    Arch Virol; 1990; 115(3-4):251-65. PubMed ID: 2260923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis.
    Dmitriev IP; Khromykh AA; Ignatyev GM; Gainullina MN; Ageenko VA; Dryga SA; Vorobyeva MS; Sandakhchiev LS
    J Biotechnol; 1996 Jan; 44(1-3):97-103. PubMed ID: 8717392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.
    Wild TF; Bernard A; Spehner D; Drillien R
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():359-67. PubMed ID: 1538193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection.
    Pugachev KV; Mason PW; Shope RE; Frey TK
    Virology; 1995 Oct; 212(2):587-94. PubMed ID: 7571428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
    Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
    J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine.
    Konishi E; Pincus S; Paoletti E; Laegreid WW; Shope RE; Mason PW
    Virology; 1992 Sep; 190(1):454-8. PubMed ID: 1326813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
    Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
    Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.
    Schäfer B; Holzer GW; Joachimsthaler A; Coulibaly S; Schwendinger M; Crowe BA; Kreil TR; Barrett PN; Falkner FG
    PLoS One; 2011; 6(9):e24505. PubMed ID: 21931732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge.
    Taylor J; Pincus S; Tartaglia J; Richardson C; Alkhatib G; Briedis D; Appel M; Norton E; Paoletti E
    J Virol; 1991 Aug; 65(8):4263-74. PubMed ID: 1830113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.